Trial
NCT02560012
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
—
Condition
Carcinoma, Renal Cell
Intervention
Sunitinib
Why stopped
Loss of laboratory performing molecular analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-12